Balyasny Asset Management
TRIL

Balyasny Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Balyasny Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-225,000
Closed -$3.95M – 2772
2021
Q3 		$3.95M Buy
+225,000
New +$2.63M 0.02% 904
2020
Q4 		– Sell
-234,122
Closed -$3.33M – 1841
2020
Q3 		$3.33M Buy
+234,122
New +$2.33M 0.02% 711
2020
Q2 		– Sell
-326,065
Closed -$1.32M – 1611
2020
Q1 		$1.32M Buy
+326,065
New +$1.23M 0.02% 697

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Balyasny Asset Management's TRIL Position: Q4 2021 in Review

Balyasny Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 225,000 shares — an estimated $3.95M sold.

Balyasny Asset Management first reported a position in TRIL in Q1 2020 and held it in 3 quarters. The position peaked at $3.95M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Balyasny Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 225,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $3.95M.
  • Balyasny Asset Management first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 3 quarters.
  • Balyasny Asset Management's Trillium Therapeutics Inc. position peaked at $3.95M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.